Table 3.
Laboratory abnormalities of the two groups
| Dose-reduced group (n = 57) | Dose-maintained group (n = 22) | |||||||
|---|---|---|---|---|---|---|---|---|
| All Grades n (%) | Grade 1/2 n (%) | Grade 3/4 n (%) | All Grades n (%) | Grade 1/2 n (%) | Grade 3/4 n (%) | p value | ||
| White blood cell count decreased | pretreatment | 2 (3) | 2 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| First 2 weeks | 10 (18) | 10 (18) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.05 | |
| First cycle | 33 (58) | 29 (51) | 4 (7) | 11 (50) | 10 (46) | 1 (5) | 0.61 | |
| Neutrophil count decreased | Pretreatment | 1 (2) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| First 2 weeks | 3 (5) | 3 (5) | 0 (0) | 1 (5) | 1 (5) | 0 (0) | 1.00 | |
| First cycle | 26 (46) | 24 (42) | 2 (3) | 7 (32) | 6 (27) | 1 (5) | 0.58 | |
| Lymphocyte count decreased | pretreatment | 17 (30) | 15 (27) | 2 (3) | 5 (23) | 5 (23) | 0 (0) | 0.58 |
| First 2 weeks | 28 (49) | 17 (30) | 11 (19) | 2 (9) | 2 (9) | 0 (0) | <0.01 | |
| First cycle | 37 (65) | 21 (37) | 16 (28) | 9 (41) | 9 (41) | 0 (0) | 0.13 | |
| Hemoglobin decreased | pretreatment | 43 (75) | 38 (67) | 5 (9) | 14 (65) | 11 (50) | 3 (14) | 0.40 |
| First 2 weeks | 38 (67) | 35 (61) | 3 (5) | 14 (65) | 14 (65) | 0 (0) | 0.80 | |
| First cycle | 48 (84) | 36 (63) | 12 (21) | 2 (9) | 2 (9) | 0 (0) | 1.00 | |
| Platelet count decreased | pretreatment | 7 (12) | 7 (12) | 0 (0) | 9 (41) | 9 (41) | 0 (0) | 1.00 |
| First 2 weeks | 37 (65) | 34 (60) | 3 (5) | 8 (37) | 7 (32) | 1 (5) | 0.03 | |
| First cycle | 50 (89) | 36 (64) | 14 (25) | 19 (86) | 17 (77) | 2 (9) | 1.00 | |
| Creatinine increased | pretreatment | 21 (37) | 20 (36) | 1 (2) | 8 (36) | 8 (36) | 0 (0) | 1.00 |
| First 2 weeks | 33 (58) | 33 (58) | 0 (0) | 13 (59) | 13 (59) | 0 (0) | 1.00 | |
| First cycle | 33 (58) | 32 (56) | 1 (2) | 13 (59) | 13 (59) | 0 (0) | 1.00 | |
| Aspartate aminotransferase increased | pretreatment | 10 (18) | 10 (18) | 0 (0) | 2 (9) | 2 (9) | 0 (0) | 0.49 |
| First 2 weeks | 34 (61) | 32 (56) | 2 (4) | 8 (36) | 8 (36) | 0 (0) | 0.08 | |
| First cycle | 45 (79) | 43 (76) | 2 (4) | 13 (59) | 11 (50) | 2 (9) | 0.09 | |
| Alanine aminotransferase increased | pretreatment | 13 (23) | 13 (23) | 0 (0) | 3 (14) | 3 (14) | 0 (0) | 0.53 |
| First 2 weeks | 26 (46) | 25 (44) | 1 (2) | 7 (32) | 7 (32) | 0 (0) | 0.79 | |
| First cycle | 39 (68) | 36 (63) | 3 (5) | 16 (73) | 14 (64) | 2 (9) | 0.89 | |
| Hypoalbuminemia | pretreatment | 38 (67) | 37 (65) | 1 (2) | 10 (45) | 9 (41) | 1 (5) | 0.12 |
| First 2 weeks | 52 (92) | 48 (84) | 4 (7) | 17 (77) | 15 (68) | 2 (9) | 0.24 | |
| First cycle | 54 (95) | 46 (81) | 8 (14) | 21 (95) | 19 (86) | 2 (9) | 1.00 | |
| Blood bilirubin increased | pretreatment | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | N.D. |
| First 2 weeks | 2 (4) | 2 (4) | 0 (0) | 1 (5) | 1 (5) | 0 (0) | 1.00 | |
| First cycle | 4 (7) | 3 (5) | 1 (2) | 2 (9) | 2 (9) | 0 (0) | 0.67 | |
| Amylase increased | pretreatment | 15 (26) | 15 (27) | 0 (0) | 4 (18) | 4 (18) | 0 (0) | 0.57 |
| First 2 weeks | 23 (40) | 21 (37) | 2 (4) | 6 (27) | 6 (27) | 0 (0) | 0.42 | |
| First cycle | 33 (58) | 23 (41) | 10 (18) | 9 (41) | 8 (36) | 1 (5) | 0.20 | |
| Hyperuricemia | pretreatment | 10 (18) | 10 (18) | 0 (0) | 6 (27) | 6 (27) | 0 (0) | 0.54 |
| First 2 weeks | 14 (25) | 14 (25) | 0 (0) | 5 (23) | 5 (23) | 0 (0) | 1.00 | |
| First cycle | 14 (25) | 14 (25) | 0 (0) | 7 (32) | 7 (32) | 0 (0) | 0.57 | |
| Hypophosphatemia | pretreatment | 4 (7) | 2 (4) | 2 (4) | 3 (14) | 2 (9) | 1 (5) | 0.40 |
| First 2 weeks | 10 (18) | 8 (15) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0.05 | |
| First cycle | 26 (46) | 21 (37) | 5 (9) | 8 (36) | 7 (32) | 1 (5) | 0.60 | |
Data are expressed in number of cases, with percentage in parenthesis